Detection of Lung Cancer by Plasma Lipids

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

558 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-13

Study Completion Date

2020-05-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. We try to establish a highly accurate method for detecting early-stage lung cancer by combining machine learning with untargeted and targeted metabolomics .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Preliminary Study on the Detection of Plasma Markers in Early Diagnosis for Lung Cancer

NCT04558255

Lung Cancer

UNKNOWN

Detecting Lung Cancer Based on Exhaled Breath

NCT04419207

Carcinoma Lung Cancer NSCLC +1 more

COMPLETED

A Study Developing a Non-invasive Urine-based Proteomic Model for Early Lung Cancer Detection.

NCT06733311

Early-Stage Lung Cancer NSCLC Pulmonary Nodule

RECRUITING

Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer

NCT05742204

Lung Cancer

ACTIVE_NOT_RECRUITING

Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy

NCT07257471

Lung Cancer (NSCLC)

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All plasma lipids were first detected by untargeted metabolomics methods and 9 feature lipids of early-stage lung cancer were selected by support vector machine algorithm. Then, a targeted metabolomics method was developed to detect the 9 lipids quantitatively based on multiple reaction monitoring mode. Finally, a detection model was established based on the 9 lipids.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Early-Stage Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants received surgery

Patients who underwent surgery at the Department of Thoracic Surgery of Peaking University People's Hospital, Jiangsu Cancer Hospital, and Beijing Haidian Hospital were enrolled with the following criteria: 1) pathologically confirmed lung cancer; 2) no history of other malignancies; 3) no anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery. Plasma samples were collected before surgery and plasma lipids were detected by mass spectrometry. Pathological diagnosis and clinical characteristics of enrolled participants were retrieved.

Plasma lipids

Intervention Type DIAGNOSTIC_TEST

Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plasma lipids

Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.

Intervention Type DIAGNOSTIC_TEST